ReviewPlant cell reports2026
PhytosRNA therapeutics: Cross-kingdom communication and translational potential of Chinese herbal medicine-derived small RNAs.
Review in Plant cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
key messageThis review discusses the mechanisms of cross-kingdom communication mediated by small RNAs derived from Chinese herbal medicines, highlights the unique advantages of their natural delivery systems, and draws insights into the key pharmacological and biotechnological challenges for their clinical translation as novel phytosRNA therapeutics. Non-coding small RNAs (sRNAs) are increasingly recognized as pharmacologically active components in Chinese herbal medicines (CHMs), performing unique cross-kingdom gene regulatory functions. The advancement of high-throughput sequencing technology and bioinformatics has enabled the discovery and functional characterization of a growing number of CHM-derived sRNAs (CHM-sRNAs). Besides their established roles in plant growth and stress responses, these sRNAs can modulate the biosynthesis of therapeutically relevant secondary metabolites in Chinese herbal medicinal plants. These CHM-sRNAs have been shown to have great stability during gastrointestinal transit, enter systemic circulation, and participate in post-transcriptional regulation in mammalian cells. In addition, their bioactivity and stability are further enhanced by nanovesicular carriers, such as plant-derived vesicles, which provide protection against enzymatic degradation and promote cellular uptake. Despite this considerable therapeutic potential, the clinical translation of CHM-sRNAs into approved RNA drugs requires resolution of several major challenges, including the optimization of pharmacokinetic properties, establishment of adequate safety-efficacy profiles, and development of reliable administration techniques. Thus, this review systematically summarizes recent progress in the functional analysis, mechanistic understanding and pharmacological profiling of CHM-sRNAs, while critically assessing their translational potential as a new category of RNA-based therapeutic agents originating from CHMs. By integrating CHM-sRNAs into modern medicine, we provide a collaborative framework that bridges the gap between traditional Chinese medicine knowledge and contemporary molecular science.
Indexed as
Identifiers
42234162What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.